OS Therapies (NYSEAMERICAN:OSTX) Stock Price Down 4.7% – Time to Sell?

Shares of OS Therapies Incorporated (NYSEAMERICAN:OSTX) fell 4.7% during mid-day trading on Wednesday . The stock traded as low as $1.80 and last traded at $1.81. 576,321 shares were traded during mid-day trading, a decline of 8% from the average session volume of 626,275 shares. The stock had previously closed at $1.90.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Lake Street Capital dropped their target price on OS Therapies from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. D. Boral Capital reissued a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a report on Thursday, April 30th. Finally, Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

OS Therapies Stock Down 4.7%

The company has a market capitalization of $80.62 million, a price-to-earnings ratio of -1.68 and a beta of -0.83. The stock’s 50-day simple moving average is $1.78 and its two-hundred day simple moving average is $1.55.

OS Therapies (NYSEAMERICAN:OSTX) last posted its quarterly earnings data on Monday, May 18th. The company reported ($0.27) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that OS Therapies Incorporated will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in OS Therapies by 16.3% during the 4th quarter. State Street Corp now owns 58,500 shares of the company’s stock worth $82,000 after purchasing an additional 8,200 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of OS Therapies in the fourth quarter worth about $39,000. Geode Capital Management LLC lifted its stake in shares of OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after buying an additional 58,350 shares in the last quarter. Susquehanna International Group LLP acquired a new position in OS Therapies during the third quarter worth about $29,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in OS Therapies during the 3rd quarter valued at about $40,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.